On November 6, 2017 Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, reported that the company is moving its conference call that was scheduled for 5:00 p.m. ET today to 8:00 a.m. ET tomorrow morning (Press release, Keryx Biopharmaceuticals, NOV 6, 2017, View Source;p=RssLanding&cat=news&id=2314738 [SID1234521608]). The company’s Prescription Drug User Fee Act (PDUFA) target action date for its supplemental new drug application for Auryxia is today, November 6, 2017. As of the time of this press release, the company has not received a response from the FDA. As such, Keryx has decided to move its third quarter financial results call to tomorrow.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To participate in the conference call, please dial 1-888-396-2320 (U.S.), 1-774-264-7560 (international) and refer to conference ID: 2193619. The call will be webcast live and accessible through the Investors section of the company’s website at www.keryx.com for a period of 15 days after the call.